In order to improve the therapeutic efficacy of CAR-T cells in solid tumors, an oncolytic adenovirus-based bioenhancer armed with chemokine CCL5, cytokines IL-12, and IFN-γ was designed and constructed, named Ki67-C3, in which a tumor-specific promoter Ki67 was used to drive the adenoviral E1A expression to control virus replication. The gene discussed is CCL5; the disease is neoplasm.